One TGR5 agonist, known as 4-Phenoxynicotinamide (MN6), could enhance insulin-stimulated glucose transport via the cAMP/PKA pathway, thereby ameliorating insulin resistance and glucose tolerance in skeletal muscle in HFD mice and C2C12 myotubes [60]. The gene discussed is GPBAR1; the disease is Insulin resistance.